Efficacy and safety of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer: Preliminary results of an open-label, single-arm, phase II study.

Hao Luo,Dan Jian,Yan Feng,Li Zhong,Qian Chen,Wei Guan,Shiheng Zhang,Jiamin Luo,Xueqing Yang,Kan Gong,Yanli Xiong,Mengxia Li,Mingfang Xu,Yu Pu,Liang Zhao,Chengyuan Qian,Nan Dai,Dong Wang

Efficacy and safety of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer: Preliminary results of an open-label, single-arm, phase II study.

2021

Hao Luo
Dan Jian
Yan Feng
Li Zhong
Qian Chen
Wei Guan
Shiheng Zhang
Jiamin Luo
Xueqing Yang
Kan Gong
Yanli Xiong
Mengxia Li
Mingfang Xu
Yu Pu
Liang Zhao
Chengyuan Qian
Nan Dai
Dong Wang

e20570Background: Although the combination of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) with platinum-etoposide chemotherapy (EP) is the preferred first-line treatment for patients with extens...

Keywords:

Internal medicine
Medicine
Oncology
Phases of clinical research
Extensive-stage small cell lung cancer
in patient
Chemotherapy
first line therapy
open label
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations